Company: ABUS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001447028-25-000083
Chunk: 4

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 4
---
 29,852 Issuance of common shares pursuant to exercise of ESPP290,438 774 (239)— — 535 Issuance of common shares pursuant to exercise of stock options101,356 458 (198)— — 260 Unrealized gain on available-for-sale securities— — — — 2,067 2,067 Net loss— — — (72,849)— (72,849)Balance at December 31, 2023169,867,414 $1,349,821 $81,270 $(1,276,652)$(48,421)$106,018 Stock-based compensation— — 8,986 — — 8,986 Issuance of common shares pursuant to the Open Market Sales Agreement16,499,999 44,123 — — — 44,123 Issuance of common shares pursuant to exercise of ESPP227,333 536 (140)— — 396 Issuance of common shares pursuant to exercise of stock options2,958,264 14,355 (6,878)— — 7,477 Issuance of common shares upon settlement of RSUs410,482 1,190 (1,190)— Unrealized gain on available-for-sale securities— — — — 286 286 Net loss— — — (69,920)— (69,920)Balance at December 31, 2024189,963,492 $1,410,025 $82,048 $(1,346,572)$(48,135)$97,366 

See accompanying notes to the consolidated financial statements.

 79

ARBUTUS BIOPHARMA CORPORATION

Consolidated Statements of Cash Flows

(Expressed in thousands of US Dollars, except share and per share amounts)

 Year ended December 31, 20242023OPERATING ACTIVITIES  Net loss$(69,920)$(72,849)Non-cash items: Depreciation1,380 1,404 Loss on impairment of lab equipment167 — Gain on sale of property and equipment— (20)Stock-based compensation expense8,986 9,301 Change in fair value of contingent consideration2,625 69 Non-cash royalty revenue(2